Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
7 hedge funds and large institutions have $82K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
38% less capital invested
Capital invested by funds: $132K → $82K (-$50K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $33K | – | – | – |
|
|
CAM
2
Cormorant Asset Management
Boston,
Massachusetts
| $27K | – | – | – |
|
|
MWNA
3
Marshall Wace North America
New York
| $10K | – | – | – |
|
|
PC
4
PointState Capital
New York
| $8K | – | – | – |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2K | -$1.18K | -11,368 | -31% |
|
|
CIA
6
Compass Ion Advisors
Conshohocken,
Pennsylvania
| $2K | +$2.07K | +20,000 | New |
|
|
MIM
7
Monashee Investment Management
Boston,
Massachusetts
| – | -$3K | -25,000 | Closed |
|
OTLKW Hedge Fund Activity: Q4 2019 in Review
7 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q4 2019, worth a combined $82K — down 38% from $132K a quarter earlier.
Fund positioning in OTLKW was balanced in Q4 2019: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Monashee Investment Management, exiting entirely with an estimated $3K sold.
- 7 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $82K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q4 2019, down 38% quarter-over-quarter.
- 1 fund opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q4 2019 and 1 closed out, a net change of 0 holders.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q4 2019 was Monashee Investment Management, an estimated $3K sold.
Based on aggregated 13F filings for Q4 2019.